BackZealand Pharma A/S. Overview

Zealand Pharma A/S. Total Current Liabilities

Track Zealand Pharma A/S.'s total current liabilities ($330M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$330.17M

Peer average / median

Loading

Zealand Pharma A/S. Total Current Liabilities History

Loading

Zealand Pharma A/S. vs. peers: Total Current Liabilities Comparison

Loading

Zealand Pharma A/S. Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Zealand Pharma A/S. (ZEAL) FAQ

The latest total current liabilities for ZEAL is $330M as of March 2022. Investors often review this figure alongside Zealand Pharma A/S.'s historical trend and sector peers before judging valuation or financial health.

A total current liabilities figure of $330M for ZEAL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ZEAL's total current liabilities ($330M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Zealand Pharma A/S.'s total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.